INVIVYD, INC. Costs and Expenses, Related Party
INVIVYD, INC. (IVVD) reported Costs and Expenses, Related Party of $4.15 million for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-31.
Discontinued › Expense Statement › Operating Expenses
us-gaap:CostsAndExpensesRelatedParty · last filed 2022-03-31
- INVIVYD, INC. costs and expenses, related party for the quarter ending 2021-12-31 was $1.89M.
- INVIVYD, INC. costs and expenses, related party for the quarter ending 2021-09-30 was $1.83M, a 527.49% increase year-over-year.
- INVIVYD, INC. costs and expenses, related party for the quarter ending 2021-06-30 was $247.00K.
- INVIVYD, INC. costs and expenses, related party for the quarter ending 2021-03-31 was $188.00K.
- INVIVYD, INC. costs and expenses, related party for fiscal 2021 was $4.15M.
| Period end | Costs and Expenses, Related Party 1 month | Costs and Expenses, Related Party 3 month | Costs and Expenses, Related Party 4 month | Costs and Expenses, Related Party 6 month | Costs and Expenses, Related Party 7 month | Costs and Expenses, Related Party 9 month | Costs and Expenses, Related Party 12 month |
|---|---|---|---|---|---|---|---|
| 2021-12-31 | $1.89M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $3.71M derived: sum of 2 quarters · filed 2022-03-31 | $3.96M derived: sum of 3 quarters · filed 2022-03-31 | $4.15M 10-K · filed 2022-03-31 | |||
| 2021-09-30 | $1.83M 10-Q · filed 2021-11-15 | $2.07M derived: sum of 2 quarters · filed 2021-11-15 | $2.26M 10-Q · filed 2021-11-15 | ||||
| 2021-06-30 | $247.00K 10-Q · filed 2021-09-20 | $435.00K 10-Q · filed 2021-09-20 | |||||
| 2021-03-31 | $188.00K derived: 10-K 12 month − 3 quarters · filed 2022-03-31 | ||||||
| 2020-12-31 | $595.00K 10-K · filed 2022-03-31 | ||||||
| 2020-09-30 | $291.00K 10-Q · filed 2021-11-15 | $291.00K 10-Q · filed 2021-11-15 | |||||
| 2020-06-30 | $0.00 10-Q · filed 2021-09-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |